Amendment of Drugs Rules

## Policy Analysis Report: The Drugs 4th Amendment Rules, 2022 **1. Executive Summary:** This report analyzes the Drugs 4th Amendment Rules, 2022, as published in the Gazette of India on April 6, 2022. This amendment modifies the existing Drugs Rules, 1945, by extending the timeframe specified in two provisos from six to eighteen months. It also omits FORM 26 D and FORM 26 E. The likely purpose is to provide more flexibility or address delays in the processes governed by the original provisos. These changes directly impact stakeholders involved in the regulatory processes governed by the Drugs Rules, 1945. **2. Introduction:** This report aims to provide a concise and informative overview of the Drugs 4th Amendment Rules, 2022, based solely on the information provided in the official notification. The analysis focuses on the specific changes introduced by the amendment and their potential implications. **3. Policy Overview:** * This is an amendment to the Drugs Rules, 1945. * **Core Objective(s) (Inferred):** To modify existing timelines and remove specific forms within the regulatory framework established by the Drugs Rules, 1945. **4. Background and Rationale:** This amendment appears to address a need for extended timelines within the existing regulatory framework of the Drugs Rules, 1945. The extension of the specified timeframe from six to eighteen months suggests that the original six-month period may have been insufficient for compliance or completion of required actions. Additionally, the removal of Forms 26 D and 26 E likely suggests a streamlining or simplification of the regulatory process by removing those forms from the existing process. **5. Key Provisions / Changes:** This amendment introduces the following key changes to the Drugs Rules, 1945: * **Amendment 1:** In Rule 153, in the second proviso, the words "within six months" are replaced with "within eighteen months." * **Original Rule:** Rule 153 contained a second proviso requiring action to be completed within six months. * **New Rule:** The same action is now permitted to be completed within eighteen months. * **Effect:** This provides a significantly extended timeframe for compliance under the conditions specified in the second proviso of Rule 153. * **Amendment 2:** In Rule 153A, in the second proviso, the words "within six months" are replaced with "within eighteen months." * **Original Rule:** Rule 153A contained a second proviso requiring action to be completed within six months. * **New Rule:** The same action is now permitted to be completed within eighteen months. * **Effect:** This provides a significantly extended timeframe for compliance under the conditions specified in the second proviso of Rule 153A. * **Amendment 3:** FORM 26 D and FORM 26 E shall be omitted. * **Original Rule:** The Drugs Rules, 1945 required Forms 26 D and 26 E to be completed for the purpose they were made for. * **New Rule:** Forms 26 D and FORM 26 E are no longer required for compliance. * **Effect:** This streamlines the process by removing Forms 26 D and FORM 26 E and reducing the regulatory burden and simplifies compliance. **6. Target Audience and Stakeholders:** Based on the text, the target audience and stakeholders directly affected by these amendments include: * Entities subject to the regulations outlined in Rules 153 and 153A of the Drugs Rules, 1945, as they now have a longer timeframe for compliance. * Entities no longer required to submit Forms 26 D and 26 E. * Pharmaceutical manufacturers, distributors, retailers, and any other parties involved in the drug regulation process as governed by the Drugs Rules, 1945. **7. Implementation Aspects (Inferred):** * **Responsible agency/bodies:** The Ministry of AYUSH, as indicated by the notification. * **Timelines:** The amendment came into force on April 6, 2022, the date of its publication in the Official Gazette. No specific procedures for implementation are detailed in the provided text beyond the immediate effect of the rule changes. * Implementation involves updating internal procedures and guidelines to reflect the extended timelines and the removal of Forms 26 D and 26 E. **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes of these amendments include: * Increased flexibility and reduced pressure on entities required to comply with Rules 153 and 153A, potentially leading to more thorough or accurate compliance. * A more streamlined and efficient regulatory process due to the removal of the forms. * Reduced administrative burden on both regulated entities and regulatory agencies. **9. Conclusion:** The Drugs 4th Amendment Rules, 2022, represent targeted adjustments to the existing Drugs Rules, 1945. The extension of timelines and the removal of specified forms aim to enhance the efficiency and practicality of the regulatory framework. These changes are significant for stakeholders operating within the pharmaceutical sector and involved in processes governed by the relevant rules. The implications should be a more navigable regulatory environment with less administrative burden.

Key Entities Referenced